Bile acids as candidate therapies for multiple sclerosis: inverse signal analysis using the FDA adverse event reporting system and preclinical validation
This two-stage investigation highlights the potential utility of pharmacovigilance-guided approaches for identifying therapeutic candidates. Bile acid derivatives, particularly UDCA, are biologically plausible candidates meriting further investigation in the context of MS.
Authors
- Yoshito Zamami (ORCID: https://orcid.org/0000-0002-7879-423X)
- Fuka Aizawa
- Takahiro Niimura (ORCID: https://orcid.org/0000-0003-2033-4246)
- Yoshihiro Uesawa (ORCID: https://orcid.org/0000-0002-5773-991X)
- Mitsuhiro Goda (ORCID: https://orcid.org/0000-0001-5345-1479)
- Yuhei Sonoda
- Mizuho Asada
- Masayuki Chuma (ORCID: https://orcid.org/0000-0002-5755-283X)
- Takahisa Mikami
- Keisuke Ishizawa
Institutions
- Hiroshima University (JP)
- Asahikawa Medical College Hospital (JP)
- Harvard University (US)
- Asahikawa Medical University (JP)
- Meiji Pharmaceutical University (JP)
- Massachusetts General Hospital (US)
- Okayama University Hospital (JP)
- Tokushima University Hospital (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1016/j.msard.2026.107113
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science